Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Larotrectinib (LOXO-101)为ATP竞争性、口服选择性抑制剂,针对原肌凝蛋白相关激酶(TRK)家族受体三个亚型(TRKA,B 和C)展现纳摩尔级别的50%抑制浓度。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 298 | 现货 | ||
5 mg | ¥ 671 | 现货 | ||
10 mg | ¥ 823 | 现货 | ||
25 mg | ¥ 1,380 | 现货 | ||
50 mg | ¥ 2,192 | 现货 | ||
100 mg | ¥ 3,274 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 739 | 现货 |
产品描述 | Larotrectinib (LOXO-101) is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors(IC50s = 2-20 nM). |
靶点活性 | Trk:2-20 nM |
体内活性 | In vivo, Larotrectinib?(60 and 200 mg/kg) reduces tumor growth in a KM12 mouse xenograft model[1]. |
动物实验 | Mice were maintained under aseptic conditions.?The care and treatment of experimental animals was in accordance with institutional guidelines.?5 × 10^5 KM12 cells were injected subcutaneously into the dorsal flank area of the mice.?Tumor volume was monitored by direct measurement with calipers and calculated by the formula: length × (width^2)/2.?Following the establishment of tumor and when the tumor size was between 150–200 mm^2, mice were randomly selected to receive diluent, 60 mg/kg/dose or 200 mg/kg/dose of Larotrectinib(LOXO-101).?LOXO-101 was administered by oral gavage once daily for 14 days.?After the last dose, tissue and blood were collected at 3, 6 and 24 hours post-treatment[1]. |
别名 | LOXO-101, ARRY-470 |
分子量 | 428.44 |
分子式 | C21H22F2N6O2 |
CAS No. | 1223403-58-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4.6 mg/mL (10.74 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.334 mL | 11.6702 mL | 23.3405 mL | 58.3512 mL |
5 mM | 0.4668 mL | 2.334 mL | 4.6681 mL | 11.6702 mL | |
10 mM | 0.2334 mL | 1.167 mL | 2.334 mL | 5.8351 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Larotrectinib 1223403-58-4 Apoptosis Tyrosine Kinase/Adaptors Trk receptor Trk Receptor LOXO101 ARRY 470 ARRY470 LOXO-101 inhibit Inhibitor ARRY-470 Tropomyosin related kinase receptor LOXO 101 inhibitor